Clinician-scientist and deep-tech founder with a record of translating platform innovations into market impact. Co-inventor of FISSEQ at Harvard—the first in situ sequencing method, foundational to spatial biology and central to 10x Genomics IP. As CSO at Ultivue, led strategic R&D, ops, and quality overhaul, restoring growth and profitability ahead of its merger with Vizgen. Proven builder of science-driven ventures.

PhD in Molecular & Cellular Pathology with deep expertise in AI applications for life science and healthcare. 10+ years leading product and marketing across growth-stage and exit-stage companies. Key roles at Seahorse Bio (acquired by Agilent), Deep Lens (acquired by Paradigm), and Ryght. Proven track record turning complex science into differentiated products and commercial success.

Engineering and AI/ML leader with 12 years at Illumina, where he helped build the software and data ecosystem that enabled its rise in precision genomics. Expert in enterprise-grade platforms for clinical genomics and patient data. Led cloud architecture at Illumina and Ryght; developed assets acquired by Verogen, CareDx, and Genome Medical. Integral to bridging deep tech with clinical and commercial impact.